Abstract
Metabolic syndrome has been associated with significantly higher risk for accelerated atheroclerosis, Type 2 diabetes mellitus, cardiovascular and cancer diseases. These risk can be detected using individual parameters of metabolic syndrome.
For primary prevention risk should not be estimated based only on the traditional isk factors (age, sex, systolic blood pressure, total cholesterol serum level and smoking), but also using new metabolit biomarkers. New trend sof personalized medicine are currently based only on the clinical factors.
Neither risk genes detection nor metabolic factors assessment has been currently used.